Why Is PHARVARIS N V (PHVS) Stock Up Today?

Pharvaris (PHVS) shares surged 11.66% to $39.36 on Tuesday, driven by the release of positive topline data from its pivotal Phase 3 CHAPTER-3 trial of deucrictibant XR for the prevention of hereditary angioedema (HAE) attacks. The trial met its primary endpoint and all secondary efficacy endpoints with statistical significance. The stock opened with a 16.3% gap up and traded as high as $48.00 before settling into a more consolidated range. The move reflects optimism about the drug’s potential for regulatory approval and commercialization.

What Happened

Pharvaris announced that its Phase 3 trial demonstrated an 83% reduction in HAE attack rates compared to placebo, meeting both primary and secondary endpoints. This milestone marks a key step toward a New Drug Application, which the company plans to submit in the first half of 2027. The announcement was widely covered, with multiple outlets highlighting the clinical and commercial significance of the results. The stock’s strong performance was also supported by Wedbush maintaining an Outperform rating and a $42 price target. The market reaction was further amplified by a broader pre-market rally in biotech and tech stocks.

What The Data Shows

The stock opened at $41.00, a 16.3% gap up from the prior close of $35.25, and reached an intraday high of $48.00 before retreating to $39.66 at the close. Volume was 2.3 million shares, more than four times the 3-month daily average. The stock has been volatile in recent weeks, having fallen 3.1% over the last eight sessions. Despite the recent insider selling by executives, including CEO Berndt Modig, the stock closed at a new 52-week high. Social chatter and analyst coverage have increased, with one recent Twitter post emphasizing the trial’s success and regulatory timeline.

What To Watch

Pharvaris has no scheduled earnings report in the near term. Investors should monitor the breadth of analyst coverage and any updates on the NDA timeline. Continued trading above $39.00 could signal sustained confidence in the company’s pipeline.